Alfred E Mann Foundation for Scientific Research
Public records show a registered, tax-exempt organization in good standing.
What it says it does
THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH (AMF) DBA HUMANNITY MEDTEC (HMT) IS A MEDICAL RESEARCH ORGANIZATION DEDICATED TO DEVELOPING AND COMMERCIALIZING INNOVATIVE SOLUTIONS FOR SIGNIFICANT UNMET MEDICAL CONDITIONS.
- Income
- $257.9 million
- Spending
- $72.7 million
- Spent on programs
- 91%
- Reserves
- 90.8 months of spending
- Largest source of income
- other income, 88%
- Employees
- 147
- Volunteers
- 4
- Highest pay
- $1.8 million, ceo/president/chair of the board
Source: Form 990 for the year ending March 31, 2026, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Strong: 100 out of 100. Higher than 96% of charities in its peer group (science, over $100m).
Reserves
35 of 35Spendable reserves would cover 90.8 months of spending.
Debt
20 of 20It owes 2% of what it owns.
Living within its means
15 of 15Income exceeded spending by 72% of income.
Income trend
15 of 15Income rose 1321% on the year before.
Spending floor
15 of 1591% of spending went to programs and raising each dollar of donations cost 0 cents.
Source: Form 990 for the year ending March 31, 2026, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 100 out of 100. Higher than 31% of charities in its peer group (science, over $100m).
Independent board
25 of 254 of 5 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending March 31, 2026, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (5)
- $36.7 million spent. NEW PROJECT DEVELOPMENTTHIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS UNDERWAY THAT ARE DIRECTED AT DEVELOPING - INNOVATIVE TECHNOLOGIES, PROJECT IDEAS AND CONCEPTS BEFORE THEY PROGRESS TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS, AND (B) ONGOING EFFORTS RELATED TO THE ADVANCEMENT OF COMMERCIAL DEVELOPMENT AND PROTECTION OF INTELLECTUAL PROPERTY OF THESE PROJECTS ACROSS THE DEVELOPMENT LIFECYCLE. THE TEAM COMPRISES THE FULL RANGE OF EXPERTISE AVAILABLE AT AMF/HMT, INCLUDING EXECUTIVE MANAGEMENT, RESEARCH SCIENTISTS AND ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS DEVELOPMENT STRATEGISTS AND ANALYSTS.EXPENSES MAY INCLUDE ONGOING PARTICIPATION IN THE DEVELOPMENT EFFORT, INCLUDING RESEARCH AND DEVELOPMENT SUPPORT, COLLABORATION MANAGEMENT, CONFERENCE AND PROFESSIONAL SOCIETY MEETING ATTENDANCE, SERVICE IN MANAGEMENT OR ON THE BOARD OF DIRECTORS OF SPINOUT ENTITIES, PATENT PROSECUTION AND THE PROSECUTION OF INFRINGEMENT ACTIONS TO PROTECT THE VALUE OF THE INTELLECTUAL PROPERTY WE CREATE. IN ADDITION TO PAYROLL EXPENSES AND DIRECT EXPENSES PAID TO OUTSIDE VENDORS FOR GOODS AND SERVICES RELATED TO PROJECTS, EXPENSES IN THIS PROGRAM MAY INCLUDE TRAVEL EXPENSES, PATENT PROSECUTION EXPENSES AND FEES, LEGAL FEES FOR EXPENSES TO CREATE, PRESERVE AND PROTECT INTELLECTUAL PROPERTY FROM INFRINGEMENT AND REMEDY PAST INFRINGEMENT, AND INCENTIVE AND OTHER COMPENSATION PAYMENTS TO EMPLOYEES AND OTHERS RELATED TO THESE PROGRAMS AND ACTIONS. IN SOME CASES, CERTAIN OF THESE EXPENDITURES MIGHT BE INCURRED LONG AFTER THE PROGRAMS HAVE BEEN LAUNCHED INTO SPINOUT COMPANIES OR LICENSED TO THIRD PARTIES.REVENUES ASSOCIATED WITH THESE PROJECTS (SOME OF WHICH MAY ACCRUE LONG AFTER THE PROJECT AND ANY RELATED PROGRAM HAVE BEEN OUTLICENSED OR LAUNCHED INTO A SPINOUT COMPANY) MAY INCLUDE: RECOVERIES OF JUDGMENTS OR SETTLEMENTS FROM PATENT INFRINGEMENT AND LICENSING MATTERS, ROYALTIES ON LICENSED PRODUCT SALES, MILESTONE PAYMENTS, ONGOING CONTRACT R&D SERVICES PROVIDED TO PARTNERS, LICENSEES AND SPINOUT COMPANIES, INTEREST, AND PROCEEDS FROM LIQUIDITY EVENTS (E.G., INITIAL PUBLIC OFFERINGS, ACQUISITIONS) INVOLVING RETAINED EQUITY INTERESTS IN PROJECTS THAT HAVE BEEN SPUN OUT AS STARTUP COMPANIES.STATUS:DESIGN AND DEVELOPMENT ACTIVITIES ARE UNDERWAY FOR A NEW BIOELECTRONIC PROGRAM BASED ON EXISTING BUSINESS CASE ANALYSES. THESE ACTIVITIES INCLUDE GENERATION OF INITIAL SYSTEM REQUIREMENTS, ASSEMBLY OF A TEAM OF KEY OPINION LEADERS WITH DOMAIN EXPERTISE, AND THE INITIATION OF SOME FUNDAMENTAL APPLIED RESEARCH IN THE AREA OF NOVEL STIMULATION TECHNIQUES, INCLUDING COMPLETION OF PRE-CLINICAL TESTING. ADDITIONALLY, THE BUSINESS DEVELOPMENT TEAM, ALONG WITH EXECUTIVE MANAGEMENT AND OTHER STAFF, PERFORMED PRELIMINARY DUE DILIGENCE ON A NUMBER OF PROJECTS.
- $17.0 million spent. NEUROMODULATION SYSTEMADVANCED IMPLANTABLE NEUROMODULATION SYSTEM DEVELOPMENT:THIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY-STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS UNDERWAY THAT ARE DIRECTED AT DEVELOPING INNOVATIVE TECHNOLOGIES, PROJECT IDEAS AND CONCEPTS BEFORE THEY PROGRESS TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS, AND (B) ONGOING EFFORTS RELATED TO THE ADVANCEMENT OF COMMERCIAL READINESS AND PROTECTION OF RELATED INTELLECTUAL PROPERTY ACROSS THE DEVELOPMENT LIFECYCLE. THE TEAM COMPRISES THE FULL RANGE OF EXPERTISE AVAILABLE AT AMF/HMT, INCLUDING EXECUTIVE MANAGEMENT, RESEARCH SCIENTISTS AND ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS DEVELOPMENT STRATEGISTS AND ANALYSTS.STATUS RESEARCH AND DEVELOPMENT ACTIVITIES ARE UNDERWAY TO ENHANCE THE CAPABILITIES OF A NEUROMODULATION SYSTEM, COMPRISED OF ADVANCED TECHNOLOGIES AND SYSTEM SOLUTIONS IN SUPPORT OF NEW BUSINESS DEVELOPMENT STRATEGIES.
- $10.0 million spent. IMPLANTABLE NEUROMODULATION PROJECT #1 TO TREAT CHRONIC DISEASE -THE AIM OF THE AMF/HMT PROGRAM IS TO DEVELOP A NEUROSTIMULATION SYSTEM THAT WILL IMPROVE MEDICAL OUTCOMES AT A LOWER COST AND/OR HIGHER PATIENT SATISFACTION THAN CURRENTLY AVAILABLE TREATMENT OPTIONS. SUCH A SYSTEM WILL CONSIST OF A FULLY IMPLANTABLE NEURAL STIMULATOR FOR SEAMLESS OPERATION AND REQUIRING MINIMAL INTERACTION FROM A PATIENT, WITH THE GOAL OF OFFERING A HIGHER LEVEL OF PATIENT SATISFACTION, ADOPTION, AND COMPLIANCE.STATUS:FINAL DESIGN VERIFICATION TESTING ACTIVITIES OF THE IMPLANTABLE DEVICE AND EXTERNALS ARE COMPLETED. A FIRST-IN-HUMAN STUDY TO ASSESS THE SYSTEM DESIGN AND THERAPY IS ONGOING.
- $2.5 million spent. IMPLANTABLE NEUROMODULATION PROJECT #2: A-$279,169.06 & B-$2,187,790.66TO TREAT A RANGE OF NEUROLOGICAL CONDITIONS. THE SYSTEM WILL CONSIST OF AN IMPLANTABLE NEURAL STIMULATOR AND EXTERNALS DESIGNED TO MAXIMIZE THERAPY OUTCOMES AND PATIENT SATISFACTION WHILE MINIMIZING SYSTEM COSTS.STATUS:PLANNING, DESIGN, AND DEVELOPMENT OF THE FIRST IN-HUMAN IMPLANT AND EXTERNALS IS UNDERWAY; FEASIBILITY PLANNING AND INITIATIVES INCLUDE PRE-CLINICAL STUDIES AND COMPUTATIONAL MODELING OF TARGETED NEURAL STRUCTURES.
- $5,451 spent. IMPLANTABLE DRUG PUMP (IDP)THE IDP IS A SOPHISTICATED, HIGHLY PROGRAMMABLE DRUG INFUSION DEVICE THAT IS IMPLANTED IN THE BODY AND REFILLED VIA A HYPODERMIC NEEDLE THROUGH THE SKIN. INFUSION RATES AND SCHEDULES MAY BE PROGRAMMED, AND VIA VARIOUS FORMS OF CATHETERS, DRUGS CAN BE DELIVERED INTRATHECALLY TO THE SPINAL COLUMN, INTO THE ABDOMEN, INTO THE BRAIN, OR INTRAVENOUSLY. STATUS: AMF/HMT HAS SOLD THE IDP TECHNOLOGY TO A STRATEGIC PARTNER THAT IS AN INTERNATIONAL MEDICAL DEVICE COMPANY. AMF/HMT CONTINUES TO SUPPORT THE STRATEGIC PARTNER AS IT CONDUCTS CLINICAL TRIALS AND READIES IT FOR COMMERCIALIZATION FOR THE BENEFIT OF PATIENTS.
Source: Form 990 for the year ending March 31, 2026, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending March 2026.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since May 1986.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.